Recently added

Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial

Kim, Sung-Bae; Barrios, Carlos; O'Shaughnessy, Joyce; Isakoff, Steven; Oliveira, Mafalda; Dent, Rebecca (American Association for Cancer Research, 2024-10-01)

Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study

Villabona, Lisa; Lawrence, Ben; Arance, Ana; Butler, Marcus; Beylot-Barry, Marie; MORTIER, Laurent; Capdevila Castillon, Jaume (ADIS, 2024-11)

Clinical Value of Liquid Biopsy in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma During Targeted Therapy

Castillo, Gloria; Martinez Perez, Paola; Gonzalez Medina, Alberto; Vila-Casadesús, Maria; Gómez-Rey, Marina; Fabregat Franco, Carles; TIAN, TIAN; Castet, Florian; Matito, Judit; Miquel Aymar, Josep Maria; Nuciforo, Paolo; Perez-Lopez, Raquel; Vivancos, Ana; SIERRA, ALEXANDRE; Macarulla, Teresa (American Association for Cancer Research, 2024-10-01)

Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer

Saini, Kamal S.; Vidal, Laura; Slebe, F.; Loibl, Sibylle; Quintana, Angela; Peg, Vicente (Elsevier, 2024-10)

Clinical Trial Data Review of the Combination FTD/TPI + Bevacizumab in the Treatment Landscape of Unresectable Metastatic Colorectal Cancer

André, Thierry; Van Cutsem, Eric; taieb, julien; Fakih, Marwan; Prager, M.D., Gerald; Ciardiello, Fortunato; Tabernero, Josep (Springer, 2024-10)

Scientia. Department of Health Digital Information Depot

VHIO - Articles científics: Recent submissions

Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial

Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study

Clinical Value of Liquid Biopsy in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma During Targeted Therapy

Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer

Clinical Trial Data Review of the Combination FTD/TPI + Bevacizumab in the Treatment Landscape of Unresectable Metastatic Colorectal Cancer

Scientia. Department of Health Digital Information Depot

VHIO - Articles científics: Recent submissions

Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial ﻿

Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study ﻿

Clinical Value of Liquid Biopsy in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma During Targeted Therapy ﻿

Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer ﻿

Clinical Trial Data Review of the Combination FTD/TPI + Bevacizumab in the Treatment Landscape of Unresectable Metastatic Colorectal Cancer ﻿

Ipatasertib plus Paclitaxel for Patients with PIK3CA/AKT1/PTEN-Altered Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer in the IPATunity130 Phase III Trial

Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study

Clinical Value of Liquid Biopsy in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma During Targeted Therapy

Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer

Clinical Trial Data Review of the Combination FTD/TPI + Bevacizumab in the Treatment Landscape of Unresectable Metastatic Colorectal Cancer